02/21/2020
7:23 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/20/2020
10:16 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/20/2020
8:44 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/20/2020
8:41 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/19/2020
12:16 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/19/2020
11:43 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/19/2020
11:34 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/19/2020
11:09 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/19/2020
11:03 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/18/2020
3:35 PM | GlaxoSmithKline (Filed by)
Morphic Holding, Inc. (Subject)
| Form SC 13D/A
| |
02/12/2020
12:30 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/11/2020
9:49 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/11/2020
6:06 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/06/2020
12:39 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/05/2020
12:36 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/03/2020
10:31 AM | GlaxoSmithKline (Filer)
| Form 6-K/A
| |
02/03/2020
5:01 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/15/2020
6:10 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/14/2020
12:40 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/14/2020
12:23 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/13/2020
1:10 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/13/2020
10:06 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/13/2020
8:55 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/13/2020
8:41 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/08/2020
11:28 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/08/2020
11:23 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/02/2020
8:08 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/23/2019
7:29 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/20/2019
3:46 PM | GlaxoSmithKline (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
12/18/2019
12:48 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/18/2019
11:43 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/17/2019
6:38 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/13/2019
11:36 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/11/2019
12:20 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/05/2019
6:41 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/02/2019
1:37 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/02/2019
1:27 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/26/2019
12:33 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/12/2019
10:35 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/08/2019
12:38 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/06/2019
11:00 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/04/2019
12:18 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/01/2019
1:21 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/01/2019
11:28 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/31/2019
5:27 PM | GlaxoSmithKline (Reporting)
Progyny, Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/31/2019
10:26 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/30/2019
1:20 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/30/2019
12:54 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/24/2019
7:36 PM | GlaxoSmithKline (Reporting)
Progyny, Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
10/22/2019
4:36 PM | GlaxoSmithKline (Reporting)
Principia Biopharma Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/21/2019
5:34 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/15/2019
12:07 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/15/2019
12:00 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/15/2019
11:54 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/15/2019
11:50 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/11/2019
12:31 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/11/2019
11:40 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/10/2019
11:29 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/01/2019
12:49 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/01/2019
10:38 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/30/2019
10:10 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/30/2019
6:00 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/26/2019
12:47 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/17/2019
12:25 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/12/2019
3:18 PM | GlaxoSmithKline (Reporting)
Turning Point Therapeutics, Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/11/2019
11:32 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/04/2019
12:56 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/04/2019
8:50 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/04/2019
8:37 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/03/2019
7:33 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/23/2019
7:28 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/22/2019
5:49 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/21/2019
6:07 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/12/2019
10:42 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/01/2019
12:10 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/01/2019
11:13 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/01/2019
7:35 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/30/2019
12:43 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/29/2019
11:15 PM | GlaxoSmithKline (Filer)
| Form EFFECT
| |
07/29/2019
8:51 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/25/2019
2:39 PM | GlaxoSmithKline (Filed by)
Morphic Holding, Inc. (Subject)
| Form SC 13D/A
| |
07/24/2019
3:58 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/24/2019
3:01 PM | Fulcrum Therapeutics, Inc. (Issuer)
GlaxoSmithKline (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/24/2019
12:53 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/24/2019
11:04 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/24/2019
10:33 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/24/2019
5:38 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/22/2019
11:37 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/19/2019
1:03 PM | GlaxoSmithKline (Subject)
JPMorgan Chase Bank, N.A. - ADR Depositary (Filed by)
| Form F-6
Registration statement under the Securities Act of 1933 for depositary shares evidenced by American depositary receipts | |
07/17/2019
6:37 PM | Fulcrum Therapeutics, Inc. (Issuer)
GlaxoSmithKline (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
07/15/2019
4:27 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/15/2019
4:07 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/15/2019
1:07 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/15/2019
9:29 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/15/2019
7:11 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/12/2019
3:23 PM | GlaxoSmithKline (Filed by)
Morphic Holding, Inc. (Subject)
| Form SC 13D
| |
07/12/2019
12:12 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/12/2019
12:04 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/10/2019
10:59 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/10/2019
5:16 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
